| Name | Codrituzumab |
|---|
| Description | Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |